A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine; Pemetrexed

Criteria

Inclusion Criteria:

• confirmed diagnosis of breast cancer

• measurable disease

• received prior anthracycline and taxane

• life expectancy > 3 months

• acceptable lab results

Exclusion Criteria:

• >3 prior regimens

• prior treatment with protocol drugs

• prior (pelvic) radiation

• active CNS metastasis

• inability to take oral vitamins